Logo

Algernon Reports Submission of IND to the US FDA for Ifenprodil to Treat COVID-19

Share this

Algernon Reports Submission of IND to the US FDA for Ifenprodil to Treat COVID-19

Shots:

  • The company has submitted the IND to the US FDA for evaluating its re-purposed drug NP-120 (Ifenprodil) in P-IIb/III study as a potential therapeutic treatment against COVID-19. The study will begin as a P-IIb study in 100 patients and with positive preliminary data- the clinical trial will move directly from a P-IIb into P-III study
  • The study will evaluate the safety and efficacy of NP-120 (20mg- q3w for 2wks.) + SOC vs SOC in confirmed COVID-19 infected hospitalized patients. The company has received clearance in Canada and has also filed for ethics approval in Australia
  • NP-120 is an NMDA receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB)- acts by preventing glutamate signaling. Algernon has filed new IP rights globally for NP-120 to treat respiratory diseases and is working to develop an injectable and slow-release formulation

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Algernon


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions